Triple

T19598406
Position Surface form Disambiguated ID Type / Status
Subject Federal Institute for Risk Assessment E470404 entity
Predicate hasSection P35 FINISHED
Object Experimental Toxicology and ZEBET NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Experimental Toxicology and ZEBET | Statement: [Federal Institute for Risk Assessment, hasSection, Experimental Toxicology and ZEBET]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Experimental Toxicology and ZEBET
Context triple: [Federal Institute for Risk Assessment, hasSection, Experimental Toxicology and ZEBET]
  • A. Toxicology in the 21st Century program
    The Toxicology in the 21st Century program is a U.S. research initiative that uses modern high-throughput and computational methods to improve the prediction of chemical toxicity and reduce reliance on traditional animal testing.
  • B. TOXNET
    TOXNET is an online database system providing access to toxicology, hazardous chemicals, and environmental health information developed by the U.S. National Library of Medicine.
  • C. ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
    ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals is an international guideline that outlines the nonclinical safety testing requirements for biotechnological products such as therapeutic proteins and monoclonal antibodies to support their clinical development and marketing authorization.
  • D. ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
    ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
  • E. Division of Chemical Toxicology
    The Division of Chemical Toxicology is a specialized unit of the American Chemical Society that focuses on the chemistry of toxic substances and their effects on biological systems.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: Experimental Toxicology and ZEBET
Target entity description: Experimental Toxicology and ZEBET is a specialized section of Germany’s Federal Institute for Risk Assessment focused on experimental toxicology and the development and promotion of alternative methods to animal testing.
  • A. Toxicology in the 21st Century program
    The Toxicology in the 21st Century program is a U.S. research initiative that uses modern high-throughput and computational methods to improve the prediction of chemical toxicity and reduce reliance on traditional animal testing.
  • B. TOXNET
    TOXNET is an online database system providing access to toxicology, hazardous chemicals, and environmental health information developed by the U.S. National Library of Medicine.
  • C. ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
    ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals is an international guideline that outlines the nonclinical safety testing requirements for biotechnological products such as therapeutic proteins and monoclonal antibodies to support their clinical development and marketing authorization.
  • D. ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
    ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
  • E. Division of Chemical Toxicology
    The Division of Chemical Toxicology is a specialized unit of the American Chemical Society that focuses on the chemistry of toxic substances and their effects on biological systems.
  • F. None of above. chosen

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d8e510024481908415c0d616fa6186 completed April 10, 2026, 11:54 a.m.
NER Named-entity recognition batch_69e6407c52c081908704d3a4dd6e853b completed April 20, 2026, 3:04 p.m.
Created at: April 10, 2026, 1:43 p.m.